Daintree Core Income Fund (ECOR)
CXA 
Summary
electroCore (ECOR) Stock Jumps 6.9%: Will It Continue to Soar?
electroCore (ECOR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
electroCore, Inc. (ECOR) Q2 2026 Earnings Call Transcript
electroCore, Inc. (ECOR) Q2 2026 Earnings Call Transcript
electroCore Q2 Earnings Call Highlights
electroCore NASDAQ: ECOR reported second-quarter 2026 revenue of $9.5 million, up approximately 28% from $7.4 million a year earlier, as growth in Veterans Affairs prescription sales and direct-to-consumer Truvaga sales lifted results. The company raised its full-year revenue outlook to growth of more than 30% over 2025 and said it is targeting positive adjusted EBITDA in the third quarter of 2027.
Daintree Core Income Fund (ECOR) FAQ
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Daintree Core Income Fund ever had a stock split?
Daintree Core Income Fund Profile
| CXA Exchange | US Country |
Overview
electroCore, Inc. is a commercial-stage bioelectronic medicine and wellness company focused on the innovation and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies. The company is at the forefront of developing technology-driven solutions for treating pain associated with migraines and episodic cluster headaches in adults, alongside supporting general health and wellbeing, and enhancing human performance. Founded in 2005 and with its headquarters in Rockaway, New Jersey, electroCore is dedicated to improving the quality of life for patients through its groundbreaking products.
Products and Services
- gammaCore
- Truvaga
- TAC-STIM
- gammaCore Sapphire
A prescription-only nVNS therapy device designated for the acute treatment of pain associated with migraine and episodic cluster headache in adults. The electroCore’s innovation, gammaCore, represents a non-invasive approach, leveraging vagus nerve stimulation to provide relief from the debilitating pain caused by migraines and cluster headaches. Its ease of use and non-invasive nature make it a valuable tool for those seeking alternatives to traditional treatment methods.
Developed by electroCore, Truvaga is a nVNS therapy aimed at supporting general health and wellbeing. This product epitomizes the company’s commitment to expanding the application of bioelectronic medicine beyond pain management, introducing a wellness aspect to their portfolio. Truvaga is designed to harness the benefits of vagus nerve stimulation in a manner that promotes overall health, providing an innovative solution for individuals looking to enhance their wellbeing.
A specialized form of nVNS developed for enhancing human performance, TAC-STIM reflects electroCore’s venture into the domain of performance optimization using bioelectronic medicine. This product is tailored for individuals seeking to improve their physical and cognitive performance through non-invasive means, marking an exciting development in the field of human enhancement technologies.
As the lead product in electroCore’s lineup, gammaCore Sapphire is a rechargeable, reloadable handheld device designed for the administration of nVNS therapy over many years. Its user-friendly, durable design ensures that patients can manage their treatment effectively and efficiently, without the need for frequent replacements or disposals. The gammaCore Sapphire stands as a testament to electroCore’s commitment to sustainability and long-term patient care.
